ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HCM Hutchmed (china) Limited

208.00
-1.00 (-0.48%)
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -0.48% 208.00 10,915 16:35:00
Bid Price Offer Price High Price Low Price Open Price
202.00 209.00 209.00 201.00 201.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations USD 630.2M USD 37.73M USD - - 1.82B
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:00 UT 3,719 208.00 GBX

Hutchmed (china) (HCM) Latest News (2)

Hutchmed (china) (HCM) Discussions and Chat

Hutchmed (china) (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2025-05-23 15:35:00208.003,7197,735.52UT
2025-05-23 15:29:34209.001225.08AT
2025-05-23 15:14:15207.591,4432,995.57O
2025-05-23 14:55:24202.4912.02O
2025-05-23 14:25:01203.1212.03O

Hutchmed (china) (HCM) Top Chat Posts

Top Posts
Posted at 24/5/2025 09:20 by Hutchmed (china) Daily Update
Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 209p.
Hutchmed (china) currently has 871,601,095 shares in issue. The market capitalisation of Hutchmed (china) is -.
This morning HCM shares opened at 201p
Posted at 16/5/2025 01:53 by lauders
The latest interview/presentation from HCM. Let's see if it is taken favourably by the market or it will be pretty much the same around here!

If it does work try accessing from here:

The full slide deck is available via the link in the top right hand corner window pane shown on the page the first link takes you to. It will be available on the HCM website in due course.

Hope the new ATTC venture proves successful. Looks interesting!
Posted at 15/5/2025 21:09 by 1jat
Oxman,
The current weakness is largely the uncertainty surrounding potential tariffs and the executive order that Trump wants to reduce the prices of US drugs. HCM seems to be slightly worse than the market. There are some recent data points that may point to reductions in expectations for 2025/26 revenues:
Takeda 12m sales (to end March) was Y48bn, this shows continued progress - HCM reported $291m for the year ending Dec 24, the Takeda value is approx $320m which will reflect some additional countries coming on stream. (Unclear whether this is ahead of expectations but Takeda shares fell on their results).
The BoA presentation confirmed that AZ is waiting for Savannah results before making an NDA for savolitinib. HCM had previously held out the possibility of a conditional approval based on Savannah - so that is a delay to revenue.
At the same meeting it was said that Sovlep approval is expected late this year.

So there is some mildly adverse news and nothing positive to report.

My view is that this may continue to drift lower, but that if Sovlep is approved and the US tariff and EO situation becomes clearer, then there is a good chance of a bounce. CKHH will also be flush with cash when its Ports deal gets through (expect this as part of the US/China resolution) and an offer to take off the market may occur.
Posted at 01/4/2025 05:35 by mcmather
"Shares of Hong Kong conglomerate CK Hutchison climbed 1% on Tuesday ahead of a deal to sell its Panama ports to a BlackRock-led group that is due to be signed by April 2"

Probably 'commentators curse' * but HCM (HKEX) presently +10.48%

*Or April Fools'!
Posted at 22/3/2025 00:45 by lauders
More good news from HCM and the share price not responding. Been an "opportunity cost" hold, but one day it may reward.

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

– First and only EZH2 inhibitor approved by the NMPA –

– HUTCHMED’s fourth product, and its first approval in hematological malignancies –
Posted at 19/3/2025 11:53 by 1jat
Sales were slightly better than I expected, with the share of revenue from Takeda rising from 33% to 38% (maybe some pre-orders to beat Trump tariffs.

The Inmagene reverse takeover of Ikena will leave HCM with a 3% stake in the enlarged entity.

They will have a post tax profit of $400m in 2025 from the disposal….and yet still no reward for shareholders.
Posted at 04/3/2025 17:12 by 1jat
Dominant shareholder CKHH will be flush with cash later this year as it is negotiating the sale of its ports to Blackrock and others. The deal will generate about US$19bn for CKHH. Plenty of firepower if they want to take HCM private or support M&A.
Posted at 21/2/2025 00:13 by mcmather
20 Feb 2025: HUTCHMED (HCM) Upgraded to Buy: Here's Why
Posted at 12/2/2025 20:28 by mcmather
Double yer money from here...

"Feb. 11, 2025, 09:25 AM

BofA raised the firm’s price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees “some regulatory headwinds potentially ahead,” the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after “strong performance in 2024” for its revised price target"
Posted at 12/12/2024 07:44 by lauders
Good news again. Will it have any effect on the share price?

Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation‑positive non‑small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR inhibitor therapy. ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI.
Posted at 14/11/2022 06:58 by lauders
Nearly +20% in HK now! Come on HCM share price at least match that!
Hutchmed (china) share price data is direct from the London Stock Exchange

Hutchmed (china) Frequently Asked Questions (FAQ)

What is the current Hutchmed (china) share price?
The current share price of Hutchmed (china) is 208.00p
How many Hutchmed (china) shares are in issue?
Hutchmed (china) has 871,601,095 shares in issue
What is the market cap of Hutchmed (china)?
The market capitalisation of Hutchmed (china) is GBP 1.82B
What is the 1 year trading range for Hutchmed (china) share price?
Hutchmed (china) has traded in the range of 187.50p to 336.00p during the past year
What is the reporting currency for Hutchmed (china)?
Hutchmed (china) reports financial results in USD
What is the latest annual turnover for Hutchmed (china)?
The latest annual turnover of Hutchmed (china) is USD 630.2M
What is the latest annual profit for Hutchmed (china)?
The latest annual profit of Hutchmed (china) is USD 37.73M
What is the registered address of Hutchmed (china)?
The registered address for Hutchmed (china) is PO BOX 309, UGLAND HOUSE, GRAND CAYMAN, KY1 1104
What is the Hutchmed (china) website address?
The website address for Hutchmed (china) is www.hutch-med.com
Which industry sector does Hutchmed (china) operate in?
Hutchmed (china) operates in the PHARMACEUTICAL PREPARATIONS sector

Your Recent History

Delayed Upgrade Clock